CHAMGAP
VERIFIEDPassed the Codex final verification and publication gate. Evidence-verification cutoff: 2026-07-24. AI was used for research and drafting; the existence of all 2 cited sources was verified at the original page, followed by blind grading, adversarial audit, and build validation. Methodology v1.0.
Verdict No. 1893 · Search date 2026-07-24 · Methodology v1.0

Prolonged Exposure therapy,
does it really help with Reduced PTSD symptoms and increased loss of diagnosis and remission?

30-Second Summary
B
Evidence Grade B · 72 · Safety caution
It increased diagnostic loss and full remission versus active psychotherapy, but attrition was substantial
Temporary distress or symptom worsening can occur early, so treatment should include assessment and safety planning by a trained clinician.
What the
research shows
The grade is B. The trial randomized 284 female veterans and active-duty personnel, 141 to Prolonged Exposure and 143 to present-centered therapy, and analyzed all participants with multiple imputation. Blinded clinical assessors found loss of diagnosis in 41.0% versus 27.8%, OR 1.80 (95% CI 1.10 to 2.96), and full remission in 15.2% versus 6.9%, OR 2.43 (1.10 to 5.37). It beat an equal-session active control, but substantial dropout gives B with 72 points.
What the
ads claim
Prolonged Exposure is a structured PTSD treatment delivered by a trained clinician. Merely repeatedly recalling trauma or enduring distress alone is not the tested intervention.
*

Useful facts when choosing a product

  • PTSD symptoms, diagnostic loss, and remission in people are graded.
  • The pivotal trial used present-centered therapy rather than a waiting list and employed assessors masked to treatment assignment.
  • Temporary distress or symptom worsening can occur early, so treatment should include clinical assessment and safety planning.
ID

Chamgap Semantic Classification Code

Candidate index · review held

X.prolonged-exposure-therapy.environmental.ptsd-symptoms-and-increased-loss-of-diagnosis-and-remission.reduce.active

Behaviors, exposures and policies > Prolonged Exposure therapy > Environmental exposure > PTSD symptoms and increased loss of diagnosis and remission > Reduction claim > Active comparator

An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.

Download semantic index (JSON) · Codebook v1

Gap Measurement · Verdict 1893 · B 72
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Across 12 sites, 284 women were randomized to Prolonged Exposure, 141, or present-centered therapy, 143, and all were analyzed using multiple imputation. Estimated CAPS means immediately after treatment were 52.9 versus 60.1, a difference of -7.2 points; differences were -6.3 at three months and -4.1 at six months, with an overall longitudinal effect of d=0.27 and P=0.03. The paper did not report 95% confidence intervals for these between-group differences. This scale has no widely validated between-group threshold, so interpretation relies on binary direct outcomes: 41.0% versus 27.8% loss of diagnosis and 15.2% versus 6.9% full remission.

02

Why this is classified as B (72)

Direct treatment targets were replicated in a publicly funded active-control trial and multiple independent studies, but attrition above 15% in both groups gives B with 72 points.

Counterpoint. Benefit does not mean universal cure. Full remission immediately after treatment was 15.2% in the pivotal trial, and dropout and residual symptoms remained.

Rejudgment record. Cross-check applied — A publicly funded active-control trial used blinded assessors and had independent replication, but treatment dropout exceeded 15% in both groups

Stored scoring profile
EndpointPSymptom or function itself is the target - including patient reports and performance tests
ReplicationR2Independently replicated across trials
IndependenceI2Decisive evidence is publicly or non-profit funded
Effect sizeE+Meets the clinically important threshold

Stored derived and displayed grades match; this is not a current recalculation or validity check (B).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Reduced CAPS PTSD severityBThe primary endpoint succeeded in all 284 randomized participants.
Increased loss of PTSD diagnosisBThe rates were 41.0% versus 27.8%, a significant difference.
Increased full remission of PTSDBRates were 15.2% versus 6.9%, although absolute remission remained limited.

Cross-check — AI research and Codex final gate

AI was used for research and drafting. Blind grading, adversarial audit, and the methodology boundary rules were then reapplied before Codex performed the final evidence, grade, copy, and build checks. If a grade cannot be narrowed, both evidence positions and their reasons are published.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Schnurr PP et al. 2007Assessor-masked randomized active-psychotherapy-controlled trial284 randomized (141/143); multiple-imputation ITT included all 284Public funding from the United States Department of Veterans Affairs Cooperative Studies Program and Department of DefensePrimary endpoint: CAPS PTSD severityEstimated CAPS means were 52.9 versus 60.1 (difference -7.2), with differences of -6.3 at three months and -4.1 at six months; confidence intervals for the differences were not reported. Diagnostic loss was 41.0% versus 27.8%, OR 1.80 (1.10 to 2.96), and full remission 15.2% versus 6.9%, OR 2.43 (1.10 to 5.37).Pivotal publicly funded active-control randomized trial
Powers MB et al. 2010Meta-analysis of controlled Prolonged Exposure studies13 studies and 675 participantsFunding not stated; no manufacturer involvement reportedPrimary PTSD symptom outcomesHedges g 1.08 versus controls (95% CI 0.69 to 1.46), P<0.001.Independent synthesis supporting replication
§

Receipt — 2 References

All 2 cited sources were verified for existence at the original page (as of 2026-07-24).

Schnurr PP, Friedman MJ, Engel CC, et al. Cognitive behavioral therapy for posttraumatic stress disorder in women: a randomized controlled trial. JAMA. 2007;297(8):820-830. PMID: 17327524. DOI: 10.1001/jama.297.8.820.
checked
Powers MB, Halpern JM, Ferenschak MP, Gillihan SJ, Foa EB. A meta-analytic review of prolonged exposure for posttraumatic stress disorder. Clin Psychol Rev. 2010;30(6):635-641. PMID: 20546985. DOI: 10.1016/j.cpr.2010.04.007.
checked
Research and draft: AI used · Cross-check: blind grading and adversarial audit
Final verification and publication gate: Codex · Evidence date: 2026-07-24 · Corrections: none

Cite this verdict

Prolonged Exposure therapy x improved PTSD symptoms and remission Evidence Grade B card
[Chamgap] Prolonged Exposure therapy x improved PTSD symptoms and remission — Evidence Grade B·72. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/mood/prolonged-exposure-therapy-ptsd-symptoms-remission/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.